Saigon Sally
27 Oct 2017
Re: ADS Offering Wait, so let me get this straight. We've got (or are in the process of getting) 262 million crispy clean smackers in the tank and the share price has just leapt to a record high. Is SS not getting something here...? Presumably once those new ADRs are issued and in circulation there will come the jolt? In a month's time?
David Global
27 Oct 2017
AIM v NASDAQ Glad the American market is driving this, they get Biotech and they get the investment case for Chi-Med unlike the short termism London market
Maru118
26 Oct 2017
Re: $262m Trump train gonna trump train
velocipede
26 Oct 2017
Re: $262m Yup - Crooked Hilary replaced by Honest Don. He he.
Maru118
26 Oct 2017
Re: $262m Lol, still laughing at the use of crooked Hillary. So crooked.
David Global
26 Oct 2017
$262m I'm curious as to the size of the offering, in that yes, we need a lot of cash to push some of these drug candidates over the line and through the regualtory process, which is very costly, but $262m??Now is certainly a good time to raise it, crooked Hilary gone, the Biotech sector firing on all cylinders etc but $262m?Could we possibly be looking to buy back a share or all of Fruquintinib global rights? Or could we be looking to do a mega deal like the one Beigene just did with Celgene?Whatever happens I am 100% confident our briliant Management Team will deploy this $262m very effectively to maximise Shareholder value
Boring Bernie
26 Oct 2017
Re: ADS Offering Price is out now, 26.5 USD, which is, more or less, £40, and better than I'd expected.
Sharpedge7
25 Oct 2017
Re: ADS Offering My guess (and hope!) is that pricing will around the current level. This is my biggest individual share. I'm essentially running profits as first bought at £3 - if only I'd never sold any.....!! I'm tempted to buy more but don't have the bottle. Agree that it makes sense to raise more money State side now.
Maru118
25 Oct 2017
Re: ADS Offering To me it just makes sense to be raising capial when the share price is high. They can get double the funds for the same equity as last time, or they can get the same funds, for half the equity as last time.Price of the stock has soared over the last few months and they're taking advantage of this, to raise large sums without having to give away as much equity as before.
Saigon Sally
25 Oct 2017
Re: ADS Offering The IPO in 2016 knocked the share price badly for a twelve month. I hope it is not double that this time. SS much poorer today than yesterday...
David Global
25 Oct 2017
Re: ADS Offering fair point Bernie..........I also note from the prospectus.."HHHL, our majority shareholder, has indicated an interest in purchasing up to $182.0 million in ADSs in the aggregate in this offering on the same terms as other investors"HHL being Hutchison Health Holdings LtdA clear and demonstrable show of confidence by our largest Shareholder...... 
-)
Boring Bernie
25 Oct 2017
Re: ADS Offering Fair play to you if you're buying all the time Davey.On the basis that I don't know what price the ADS's will be offered at, I've reduced my holding by about a third
David Global
25 Oct 2017
ADS Offering Today's offering is over twice the size of the NASDAQ IPO in 2016!Why raise cash now? Late stage pipeline development is extremely expensive. I also think some of the proceeds could be used to buy back a share of an asset, like they did with AZ and Savolitinib....For example, could we be buying 100% China rights to Fruquintinib or Savolitinib leaving Lilly and AZ with ex China rights?Just a thought because this is a large amount of cash being raised, so I suspect it's not just for general purposes!!!! on another note, I'm also reassured because the Directors have large stakes and continue to buy, even at these prices, so they are very confident ;o-)I continue to buy, especially after today's announcement!
David Global
22 Oct 2017
Potential Valuation An extract from a recent post I did on advfnI like to use sector and geographic average P/E, P/S and EV/EBITDA metrics which I blend together to come up with a valuation:-P/E = 79P/S = 22EV/EBITDA = 70Analyst 2025 Revenue forecast = $1006,000,000 (assumes pipeline success)Blended mcap = $21.4bn = £268 per sharePersonally I think the revenue number will be much higher than $1bn because the commercial arm alone is growing at an astonishing rate....so my prediction is conservative and it a;so happens to tie in to Tony Hilton's view in the Evening Standar
David Global
22 Oct 2017
Re: New Reuters article from 19th Oct [link] article also explains some of the regualtory reforms This wil;l be a $20bn mcap Company in the next 5 years IMOI continue to buy
